Document:

First Amendment to Unsecured Credit Agreement

 Exhibit 10.3 
 FIRST AMENDMENT TO UNSECURED CREDIT AGREEMENT 
 This First Amendment
to Unsecured Credit Agreement (the “Amendment”) is made as of March 30, 2012 (the “Effective Date”), by and among BIOMED REALTY, L.P. (“Borrower”), KEYBANK NATIONAL ASSOCIATION, as
“Administrative Agent,” and such of the lenders (“Lenders”) party to the Loan Agreement (defined below) constituting the Requisite Lenders under the Loan Agreement, and, solely for the purpose of agreeing to the terms and
conditions of Section 5 below, BIOMED REALTY TRUST, INC., a Maryland corporation (“Guarantor”). 
 R E C
I T A L S 
 A. Borrower, Administrative Agent, the Lenders executing this Amendment and certain other Lenders have entered
into that certain Unsecured Credit Agreement dated as of July 14, 2011 (as it may be further amended, the “Loan Agreement”). All capitalized terms used herein and not otherwise defined shall have the meanings given to them in
the Loan Agreement. 
 B. Concurrently herewith, Administrative Agent and certain lenders have agreed to provide Borrower with
an unsecured term credit facility with an initial Aggregate Commitment of $400,000,000, subject to future increase to up to $500,000,000 (the “Related Facility”), as evidenced by that certain Unsecured Term Credit Agreement of even
date herewith by and among Borrower, Administrative Agent and certain other lenders as more particularly identified therein (the “Unsecured Term Credit Agreement”). 

C. Borrower has requested that Administrative Agent and Lenders agree to amend the Loan Agreement as provided herein. 

NOW, THEREFORE, with reference to the foregoing Recitals, all of which are incorporated herein by this reference, for valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 

 AGREEMENTS 
 1. Amendments to Defined Terms. The following Definitions from Article I of the Loan Agreement are modified as follows: 
 A. The defined term “Gross Asset Value” is hereby deleted and replaced with the following: 
 ““Gross Asset Value” means, as of any day, an amount equal to the sum of the following assets then owned by a member of the Consolidated Group or an Investment Affiliate and valued
as follows: (i) Adjusted NOI attributable to Projects owned by a member of the Consolidated Group (or the Consolidated Group Pro Rata Share thereof with respect to Projects owned by an Investment Affiliate) (excluding any such portion of such
Adjusted NOI attributable to (a) Projects that were Unstabilized Projects at any time during the Fiscal Quarter with respect to which Adjusted NOI is determined, (b) Projects acquired after the first day of such Fiscal Quarter, or
(c) Projects disposed of during or after such Fiscal Quarter), divided by the Capitalization Rate; plus, without duplication, (ii) with respect to each such Project that was an Unstabilized Project, the greater of
(a) the portion of such Adjusted NOI attributable to such Project (or the Consolidated Group Pro Rata Share thereof with respect to any such excluded Project owned by an Investment Affiliate), divided by the Capitalization Rate and
(b) the Consolidated Group’s GAAP cost basis (or the Consolidated Group Pro Rata Share thereof with respect to any such excluded Project owned by an Investment Affiliate) in such Project; plus (iii) the Consolidated
Group’s GAAP cost basis of all Projects acquired after the first day of such Fiscal Quarter and on or prior to such date of determination (or the Consolidated Group Pro Rata Share thereof with respect to any such acquired Project owned by an
Investment Affiliate); plus (iv) the Consolidated Group’s GAAP cost basis of all raw land held for development as of such date (or the Consolidated Group Pro Rata Share thereof with respect to any such land owned by an Investment
Affiliate) (provided that the amount contributed to Gross Asset Value under this clause (iv) shall not exceed 10% of the total Gross Asset Value); plus (v) note receivables (valued at par value less impairments in accordance with
GAAP) which are Permitted Investments per the terms of Section 6.13(d) hereinbelow (provided that the amount contributed to Gross Asset Value under this clause (v) shall not exceed 10% of the total Gross Asset Value); plus
(vi) cash and Cash Equivalents of the Consolidated Group as of such date of determination. For purposes of determining Gross Asset Value, Projects with negative Adjusted NOI shall be excluded from clause (i) of the preceding
sentence.” 
 B. The defined term “Negative Pledge” is hereby deleted and replaced with the following 

““Negative Pledge” means a Contractual Obligation (other than the Loan Documents and the documents executed in
connection with the Related Facility) that contains a covenant binding on any owner of a Project that prohibits Liens on any of such owner’s Projects, other than any such covenant contained in a Contractual Obligation (other than the Loan
Documents and the documents executed in connection with the Related Facility) (a) granting or relating to a particular Lien on a Project or on an equity interest in a Project which prohibits further Liens on such Project and/or on the direct or
indirect ownership interests in the entity owning such Project, or (b) requiring that the Consolidated Group maintain a pool of unencumbered properties of a size determined by reference to the total amount of Total Unsecured Indebtedness of the
Consolidated Group on substantially similar terms to those provisions contained herein regarding the Unencumbered Projects, but that do not generally prohibit the encumbrance of the Borrower’s or the Consolidated Group’s assets, or the
encumbrance of any specific assets.” 
 C. The defined term “Total Unsecured Indebtedness” is hereby deleted and
replaced with the following 
 ““Total Unsecured Indebtedness” means, as of any date, (A) Consolidated
Outstanding Indebtedness (including without limitation all Indebtedness under this Agreement and the Unsecured Term Credit Agreement) less (B) all Secured Indebtedness of the Consolidated Group less (C) the Consolidated Group Pro Rata
Share of all Secured Indebtedness of Investment Affiliates, provided that any Secured Indebtedness which both (i) is secured solely by a pledge of stock, partnership interests, membership interests or other ownership interests in a Person
owning a Project or Projects and (ii) is a recourse obligation of Borrower or Parent shall be included in “Total Unsecured Indebtedness” notwithstanding clauses (B) and (C) of this sentence.” 

  
 - 2 -

 D. The defined term “Designated Deposit Account” is hereby deleted from the Loan
Agreement. 
 2. Additional Defined Terms. Article 1 of the Loan Agreement is hereby amended by the addition of the following new defined
terms having the following meanings as provided herein: 
 A. “Related Facility” means the credit facility made
available to Borrower under the Unsecured Term Credit Agreement. 
 B. “Unsecured Term Credit Agreement” means
that certain Unsecured Credit Agreement dated as of March 30, 2012 by and among the Borrower, KeyBank and certain other lenders identified therein, as it may be amended or modified from time to time. 

3. Amendments to Loan Agreement. The Loan Agreement is hereby amended as follows: 

A. Loans Generally. The last grammatical sentence contained in Section 2.1(d) of the Loan Agreement is hereby deleted in its
entirety and replaced with the following: 
 “Upon satisfaction or waiver of the applicable conditions set forth in
Article 8, all Advances shall be credited on that date in immediately available funds to the account designated by Borrower.” 
 B. Events of Default. Section 9.1(g) of the Loan Agreement is hereby deleted in its entirety and replaced with the following: 

“(g) Borrower or Guarantor or any other member of the Consolidated Group fails to perform or observe any other term, covenant or
agreement on its part to be performed or observed within any applicable notice and cure period, or suffers any such event of default to occur, in connection with (A) any present or future Indebtedness under the Unsecured Term Credit Agreement
or any other present or future Indebtedness (other than Non-Recourse Indebtedness) having an outstanding principal balance, individually or in the aggregate of $25,000,000 or more, or (B) any present or future Non-Recourse Indebtedness having
an outstanding principal balance, individually or in the aggregate, of $65,000,000 or more (provided, that for the purpose of this clause (g), the principal amount of Indebtedness consisting of a Swap Agreement shall be the amount which is then
payable by the counterparty to close out the Swap Agreement); or...” 

  
 - 3 -

 C. Remedies Upon Event of Default. Section 9.2(d) of the Loan Agreement is
hereby deleted in its entirety and replaced with the following: 
 “(d) The order and manner in which the Lenders’
rights and remedies are to be exercised shall be determined by the Requisite Lenders in their sole discretion, and all payments received by the Administrative Agent and the Lenders, or any of them, shall be applied first to the costs and expenses
(including reasonable attorneys’ fees and disbursements and the reasonably allocated costs of attorneys employed by the Administrative Agent or by any Lender) of the Administrative Agent and of the Lenders, then to the repayment of Swing Loans,
and thereafter paid pro rata to the Lenders in the same proportions that the aggregate Obligations owed to each Lender under the Loan Documents bear to the aggregate Obligations owed under the Loan Documents to all the Lenders, without priority or
preference among the Lenders. Regardless of how each Lender may treat payments for the purpose of its own accounting, for the purpose of computing the Obligations hereunder and under the Notes, payments shall be applied first, to the costs and
expenses of the Administrative Agent and the Lenders, as set forth above, second, to the payment of interest and principal (in that order) due on Swing Loans, third, to the payment of accrued and unpaid interest due under any Loan Documents to and
including the date of such application (ratably, and without duplication, according to the accrued and unpaid interest due under each of the Loan Documents), and fourth, pari passu to the payment of all other amounts (including principal and fees)
then owing to the Administrative Agent or the Lenders under the Loan Documents. No application of payments under this clause (d) will cure any Event of Default, or prevent acceleration, or continued acceleration, of amounts payable under the
Loan Documents, or prevent the exercise, or continued exercise, of rights or remedies of the Lenders hereunder or thereunder or at Law or in equity.” 
 4. Schedule of Subsidiaries and Projects. As of the Effective Date, Schedule 4.4 (Subsidiaries) and Schedule 4.19 (Projects) to the Loan Agreement are hereby deleted in their entirety and replaced
with the attached Schedule 4.4 and Schedule 4.19. 
 5. Guarantor. Guarantor (a) consents to the terms
and conditions of this Amendment; and (b) reaffirms the Guaranty and confirms and agrees that, notwithstanding this Amendment and consummation of the transactions contemplated thereby, the Guaranty and all of such Guarantor’s covenants,
obligations, agreements, waivers, and liabilities set forth in the Guaranty continue in full force and effect in accordance with their terms, modified only to the extent specifically set forth in this Amendment. 

6. Full Force and Effect. Except as amended hereby, the terms and provisions of the Loan Agreement and the Loan Documents remain unchanged, are
and shall remain in full force and effect unless and until modified or amended in writing in accordance with their terms, and are hereby ratified and confirmed. Except as expressly provided herein, this Amendment shall not constitute an amendment,
waiver, consent or release with respect to any provision of any Loan Document, a waiver of any default or Event of Default under any Loan Document, or a waiver or release of any of the Lenders’ rights and remedies (all of which are hereby
reserved). The Borrower expressly ratifies and confirms the confession of judgment (if applicable) and waiver of jury trial provisions contained in the Loan Documents. 
 7. References to Loan Documents; Capitalized Terms. Any and all references to any Loan Document in any other Loan Document shall be deemed to refer to such Loan Document as amended by this
Amendment. This Amendment is deemed incorporated into each of the Loan Documents. Any initially capitalized terms used in this Amendment without definition shall have the meanings assigned to those terms in the Loan Documents. To the extent that any
term or provision of this Amendment is or may be inconsistent with any term or provision in any Loan Document, the terms and provisions of this Amendment shall control. 
 8. Successors and Assigns. This Amendment will be binding upon and inure to the benefit of the Borrower and the Lenders and their respective heirs, executors, administrators, successors and
assigns. 

  
 - 4 -

 9. Governing Law. This Amendment shall be governed by and construed in accordance with the laws of
the State of New York. 
 10. Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together
shall constitute one agreement, and any of the parties hereto may execute this Amendment by signing any such counterpart. 

[Remainder of Page Left Intentionally Blank.] 

  
 - 5 -

 IN WITNESS WHEREOF, the parties have executed and delivered this Amendment as of the date
first written above. 
  

							
		 	 BORROWER:
  

BIOMED REALTY, L.P., a Maryland limited partnership

			
		 	By:	 	BioMed Realty Trust, Inc., its sole General Partner
				
		 		 	By:	 	/s/ Robert Sistek
		 		 	Name: Robert Sistek
		 		 	Title: Vice President, Finance
		
		 	 Address:
  

BioMed Realty, L.P.
 17190 Bernardo Center
Drive
 San Diego, CA 92128
 Attn: Vice
President, Real Estate Counsel
 Telephone: (858) 207-5850
 Facsimile: (858) 485-9843

		
		 	 GUARANTOR (solely with respect to Section 5):

 
 BIOMED REALTY TRUST, INC., a Maryland corporation

			
		 	By:	 	/s/ Robert Sistek
		 	Name: Robert Sistek
		 	Title: Vice President, Finance
		
		 	 Address:
  

BioMed Realty, L.P.
 17190 Bernardo Center
Drive
 San Diego, CA 92128
 Attn: Vice
President, Real Estate Counsel
 Telephone: (858) 207-5850
 Facsimile: (858) 485-9843

  
 Signature Page

							
		 	 ADMINISTRATIVE AGENT:
  

KEYBANK NATIONAL ASSOCIATION,
 as
Administrative Agent

			
		 	By:	 	/s/ Michael P. Szuba
		 	Print Name: Michael P. Szuba
		 	Title: Vice President
		
		 	 Address:
  

KeyBank—Real Estate Capital
 127 Public
Square, 8th Floor
 Mail Code: OH-01-27-0839
 Cleveland, OH 44114
 Telephone: (216) 689-5984

Facsimile: (216) 689-4997
 Attention:
Michael P. Szuba
  
 LENDERS:

 

		
	 Commitment: $86,500,000
	 	 KEYBANK NATIONAL ASSOCIATION,
 individually and as Administrative Agent

			
		 	By:	 	/s/ Michael P. Szuba
		 	 Print Name: Michael P. Szuba
 Title: Vice President

		
		 	 Address:
  

KeyBank—Real Estate Capital
 127 Public
Square, 8th Floor
 Mail Code: OH-01-27-0839
 Cleveland, OH 44114
 Phone: (216) 689-5989

Facsimile: (216) 689-4997
 Attention:
Michael P. Szuba

  
 Signature Page

							
	Commitment: $86,500,000	 	 WELLS FARGO BANK, N.A., individually and
 as Syndication Agent

			
		 	By:	 	/s/ Dale Northup
		 	Print Name: Dale Northup
		 	Title: Vice President
		
		 	 Address:
  

Wells Fargo Bank, N.A.
 401 B Street, Suite
1100
 San Diego, CA 92101
 Telephone:
(619) 699-3025
 Facsimile: (619) 699-3105
 Attention: Dale Northup, Vice President

  
 Signature Page

							
	Commitment: $60,000,000	 	 U.S. BANK NATIONAL ASSOCIATION, 
 a national banking association, individually and as
 Documentation Agent

			
		 	By:	 	/s/ Michael Paris
		 	 Name: Michael Paris
 Title: Vice President

		
		 	 Address:
  

U.S. Bank National Association
 4747 Executive
Drive, 3rd Floor

San Diego, CA 92121
 Telephone:
(858) 334-0703
 Facsimile: (858) 334-0797
 Attention: Michael Parris

  
 Signature Page

							
	Commitment: $60,000,000	 	RAYMOND JAMES BANK, N.A.
			
		 	By:	 	/s/ Thomas G. Scott
		 	 Print Name: Thomas G. Scott
 Title: Senior Vice President

		
		 	 Address:
  

710 Carillon Parkway
 St. Petersburg, FL
33716
 Telephone: (727) 567-4196

Facsimile: (727) 567-8830
 Attention: Thomas
G. Scott

  
 Signature Page

							
	Commitment: $50,000,000	 	UBS LOAN FINANCE LLC
			
		 	By:	 	/s/ Irja R. Otsa
		 	 Print Name: Irja R. Otsa
 Title: Associate Director

		 		 		 	
		 	By:	 	/s/ Mary E. Evans
		 	 Print Name: Mary E. Evans
 Title: Associate Director

		
		 	 Address:
  

677 Washington Boulevard
 Stamford, CT
06901
 Telephone: (203) 719-6391

Facsimile: (203) 719-3888
 Attention: Jitesh
Hotwani

  
 Signature Page

							
	Commitment: $50,000,000	 	MORGAN STANLEY BANK, N.A.
			
		 	By:	 	/s/ Nick Zangari
		 	 Print Name: Nick Zangari
 Title: Authorized Signatory

		
		 	 Address:
  

One Utah Center
 201 South Main Street, 5th Floor
 Salt Lake City, UT 84111
 Telephone: (801) 236-3655

Facsimile: (718) 233-0967
 Attention: Carrie
D. Johnson

  
 Signature Page

							
	Commitment: $50,000,000	 	 DEUTSCHE BANK TRUST COMPANY
 AMERICAS

			
		 	By:	 	/s/ James Rolison
		 	 Print Name: James Rolison
 Title: Managing Director

		 		 		 	
		 	By:	 	/s/ Perry Forman
		 	 Print Name: Perry Forman
 Title: Director

		
		 	 Address:
  

Deutsche Bank Trust Company Americas
 60 Wall
Street
 Mail Stop: NYC60-1104
 New
York, NY 10005-2836
 Telephone: (212) 250-4075
 Facsimile: (212) 797-4885
 Attention: Bryan Whalen, Vice President

  
 Signature Page

  

							
	Commitment: $43,000,000	 	SUMITOMO MITSUI BANKING CORPORATION
				
		 	By:	 		 	 
		 	 Print Name:
	 	 
		 	Title:	 	 
		
		 	 Address:
  

601 South Figueroa Street, Suite 1800
 Los
Angeles, CA 90017
 Telephone: (213) 452-7800
 Facsimile: (213) 623-6832
 Attention: J.D. Benko

  
 Signature Page

							
	Commitment: $43,000,000	 	RBS CITIZENS, N.A.
			
		 	By:	 	/s/ Matthew Shmelter
		 	 Print Name: Matthew Shmelter
 Title: Vice President

		
		 	 Address:
  

1215 Superior Avenue-
6th Floor

Mailcode: OHS-675
 Cleveland, OH 44114

Telephone: (216) 277-0388
 Facsimile:
(216) 277-7106
 Attention: Samuel Bluso

  
 Signature Page

							
	Commitment: $43,000,000	 	REGIONS BANK
			
		 	By:	 	/s/ Paul E. Burgan
		 	 Print Name: Paul E. Burgan
 Title: Vice President

		
		 	 Address:
  

3050 Peachtree Road NW, Suite 400
 Atlanta, GA
30305
 Telephone: (404) 995-7648

Facsimile: (404) 279-7475
 Attention: Paul
Burgan, Vice President

  
 Signature Page

							
	Commitment: $43,000,000	 	PNC BANK, NATIONAL ASSOCIATION
			
		 	By:	 	/s/ Tyler Lowry
		 	 Print Name: Tyler Lowry
 Title: Vice President

		
		 	 Address:
  

249 Fifth Avenue
 One PNC Plaza,
P1-POPP-19-3
 Pittsburgh, PA 15222

Telephone: (412) 768-1821
 Facsimile:
(412) 762-6500
 Attention: Tyler Lowry, Vice President

  
 Signature Page

							
	Commitment: $30,000,000	 	COMERICA BANK
			
		 	By:	 	/s/ Casey L. Stevenson
		 	 Print Name: Casey L. Stevenson
 Title: Vice President

		
		 	 Address:
  

3551 Hamlin Road, MC2390
 Auburn Hills, MI
48326
 Telephone: (248) 371-6283

Facsimile: (248) 371-7920
 Attention:
Charles Weddell, Vice President

  
 Signature Page

							
	Commitment: $30,000,000	 	TD BANK, N.A.
			
		 	By:	 	/s/ Mauricio Duran
		 	 Print Name: Mauricio Duran
 Title: Vice President

		
		 	 Address:
  

Commercial Real Estate Lending
 TD Bank,
N.A.
 200 State Street, 8th Floor

Boston, MA 02109
 Telephone:
(617) 737-3626
 Facsimile: (617) 737-0238
 Attention: Mauricio Duran, Vice President

  
 Signature Page

							
	Commitment: $25,000,000	 	SOVEREIGN BANK
			
		 	By:	 	 
		 	 Print Name: Peter A. Olivier
 Title: Senior Vice President

		
		 	 Address:
  

75 State Street
 Boston, MA 02109

Telephone: (617) 346-7314
 Facsimile:
(617) 757-5852
 Attention: Amit Shah, Credit Officer

  
 Signature Page

							
	Commitment: $10,000,000	 	 THE BANK OF EAST ASIA, LIMITED, LOS
 ANGELES BRANCH

			
		 	By:	 	 
		 	 Print Name: Chong Tan
 Title: Vice President and Credit Manager

		 		 		 	
		 	By:	 	 
		 	 Print Name: Victor Li
 Title: General Manager

		
		 	 Address:
  

388 East Valley Boulevard, Suite 218
 Alhambra,
CA 91801
 Telephone: (626) 656-8838

Facsimile: (626) 656-8833
 Attention:
Jonathan Kuo

  
 Signature Page

							
	Commitment: $10,000,000	 	BANK HAPOALIM BM
			
		 	By:	 	 
		 	 Print Name: Charles McLaughlin
 Title: Senior Vice President

		 		 		 	
		 	By:	 	 
		 	 Print Name: Frederic Becker
 Title: Senior Vice President

		
		 	 Address:
  

1177 Avenue of the Americas
 New York, NY
10036
 Telephone: (212) 782-2342

Facsimile: (212) 782-2382
 Attention:
Charles McLaughlin,
             Senior Vice President

  
 Signature Page

							
	Commitment: $10,000,000	 	 MEGA INTERNATIONAL COMMERCIAL
 BANK CO., LTD. NEW YORK BRANCH

			
		 	By:	 	/s/ Priscilla Hsing
		 	 Printed Name: Priscilla Hsing
 Title: VP & DGM

		
		 	 Address:
  

65 Liberty Street
 New York, NY 10005

Telephone: (212) 815-9107
 Facsimile:(212)
766-5006
 Attention: Ifen Lee

  
 Signature Page

							
	Commitment: $10,000,000	 	LAND BANK OF TAIWAN, NEW YORK BRANCH
			
		 	By:	 	 
		 	 Print Name: Henry Leu
 Title: Senior Vice President and General Manager

		
		 	 Address:
  

100 Wall Street,
14th Floor

New York, NY 10005
 Telephone:
(917) 542-0232
 Facsimile: (917) 542-0288
 Attention: Mitch Chang, Manager

  
 Signature Page

							
	Commitment: $10,000,000	 	 CHANG HWA COMMERCIAL BANK, LTD.,
 NEW YORK BRANCH

			
		 	By:	 	/s/ Eric Y.S. Tsai
		 	 Print Name: Eric Y.S. Tsai
 Title: Vice President and General Manager

		
		 	 Address:
  

685 Third Avenue,
29th Floor

New York, NY 10017

  
 Signature Page

 SCHEDULE 4.4 

SUBSIDIARIES 
  

							
	 NAME OF SUBSIDIARY
	  	 FORM OF LEGAL ENTITY
	  	 OWNERSHIP
	  	JURISDICTION
	 1. BioMed Realty, L.P.
	  	Limited Partnership	  	0.2% GP Interest by BioMed Realty Trust, Inc. 97.9% LP Interest by BioMed Realty Trust, Inc. 1.9% LP Interest by others	  	Maryland
				
	 2. BioMed Realty Holdings, Inc.
	  	Corporation	  	100% by BioMed Realty , L.P.	  	Maryland
				
	 3. BioMed Realty Trust, Inc. REIT Qualification Trust
	  	Trust	  	 100% Beneficiary is BioMed

Realty Holdings, Inc.
	  	California
				
	 4. BMR-GP LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 5. BioMed Realty LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 6. BioMed Realty Development LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 7. BMR-JV I Holdings LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 8. BMR-JV II Holdings LLC
	  	Limited Liability Company	  	 100% by BioMed
 Realty
Holdings, Inc.
	  	Delaware
				
	 9. BioMed Ventures LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 10. BMV Direct LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 11. BMR-217th Place LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 12. BMR-270 Albany Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 13. BMR-34790 Ardentech Court LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 14. BMR-34175 Ardenwood Boulevard LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware

							
	 15. 34175 Ardenwood Venture, LLC
	  	Limited Liability Company	  	 87.5% Membership Interest by BMR-34175 Ardenwood Boulevard LLC

 
 12.5% Membership Interest by Tarlton-Wohl Venture Nine, LLC
	  	Delaware
				
	 16. BMR-Ardsley Park LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 17. BMR-8808 Balboa Avenue LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	California
				
	 18. BMR-Bayshore Boulevard LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 19. BMR-6411 Beckley Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 20. Guilford Real Estate Trust 1998-1
	  	Grantor Trust	  	100% Beneficiary is BioMed Realty, L.P., Trustee is BMR-6411 Beckley Street LLC	  	Utah
				
	 21. BMR-Belward Campus Drive LSM LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Maryland
				
	 22. BMR-9920 Belward Campus Q LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Rhode Island
				
	 23. BMR-17190 Bernardo Center Drive LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 24. BMR-Blackfan Circle LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 25. BMR-Bridgeview LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 26. BMR-Bridgeview II LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 27. BMR-Broadway LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 28. BMR-Bunker Hill LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware

							
				
	 29. BMR-58 Charles Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 30. BMR-134 Coolidge Avenue LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 31. BMR-Cray LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 32. BMR-6300 Dumbarton Circle LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 33. BMR-350 E Kendall F LLC
	  	Limited Liability Company	  	100% by BMR-PR II LLC	  	Delaware
				
	 34. BMR-650 E Kendall B LLC
	  	Limited Liability Company	  	100% by BMR-PR II LLC	  	Delaware
				
	 35. BMR-475 Eccles Avenue LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 36. BMR-2600 Eisenhower Road LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 37. BMR-201 Elliott Avenue LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 38. BMR-21 Erie Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 39. BMR-40 Erie Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 40. BMR-Executive Drive LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 41. BMR-4570 Executive Drive LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 42. BMR-500 Fairview Avenue LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 43. BMR-530 Fairview Avenue LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware

							
				
	 44. BMR-2282 Faraday Avenue LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 45. BMR-Forbes Boulevard LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 46. BMR-Fresh Pond Research Park LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 47. BMR-700 Gateway LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 48. BMR-750,800,850 Gateway LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 49. BMR-900 Gateway LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 50. BMR-1000 Gateway LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 51. BMR-Gateway/Oyster LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 52. BMR-Gazelle LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 53. BMR-350 George Patterson Boulevard LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 54. BMR-7 Graphics Drive LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 55. BMR-Hampshire LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 56. BMR-201 Industrial Road LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware

							
				
	 57. BMR-3525 John Hopkins LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 58. BMR-3545-3575 John Hopkins LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 59. BMR-6500 Kaiser Drive LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 60. BMR-450 Kendall Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 61. BMR-500 Kendall Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 62. BMR-Kendall Development LLC
	  	Limited Liability Company	  	100% by BMR-PR II TRS LLC	  	Delaware
				
	 63. BMR-Kendall Holdings LLC
	  	Limited Liability Company	  	100% by BMR-PR II TRS LLC	  	Delaware
				
	 64. BMR-145 King of Prussia Road GP LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 65. BMR-145 King of Prussia Road LP
	  	Limited Partnership	  	 99.5% LP Interest of BioMed Realty, L.P.
  

0.5% GP Interest of BMR-145 King of Prussia Road GP LLC
	  	Delaware
				
	 66. BMR-Landmark at Eastview LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 67. 10165 McKellar Court, L.P.
	  	Limited Partnership	  	 22% GP Interest by BMR-10165 McKellar Court GP LLC
  

78% LP Interest by Quidel Corporation
	  	California
				
	 68. BMR-10165 McKellar Court GP LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	California
				
	 69. BMR-Medical Center Drive LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 70. BMR-3450 Monte Villa Parkway LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware

							
				
	 71. BMR-6114-6154 Nancy Ridge Drive LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 72. BMR-6828 Nancy Ridge Drive LLC
	  	Limited Liability Company	  	 100% by BioMed Realty, L.P.
  

BioMed Realty LLC is Managing Member
	  	Delaware
				
	 73. BMR-One Research Way LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 74. BMR-180 Oyster Point LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 75. BMR-200 Oyster Point LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 76. BMR-Pacific Center LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 77. BMR-Pacific Research Center LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 78. BMR-3500 Paramount Parkway LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 79. BMR-Patriot LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 80. BMR-335-395 Phoenixville Pike LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 81. BMR-PR II LLC
	  	Limited Liability Company	  	20% BMR-JV I Holdings LLC, 80% Prudential	  	Delaware
				
	 82. BMR-PR II TRS LLC
	  	Limited Liability Company	  	20% BMR-JV II Holdings LLC, 80% Prudential	  	Delaware
				
	 83. BMR-Research Boulevard LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware

							
				
	 84. BMR-Road to the Cure LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 85. BMR-Rogers Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 86. BMR-10240 Science Center Drive LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 87. BMR-10255 Science Center LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 88. BMR-Shady Grove Road HQ LLC
	  	Limited Liability Company	  	100% by BMR-Shady Grove Holdings LLC	  	Maryland
				
	 89. BMR-Shady Grove Holdings LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 90. BMR-Shady Grove B LLC
	  	Limited Liability Company	  	100% by BMR-Shady Grove Holdings LLC	  	Delaware
				
	 91. BMR-Shady Grove D LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 92. BMR-200 Sidney Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 93. BMR-Sorrento Plaza LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 94. BMR-Sorrento Valley Boulevard LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 95. BMR-11388 Sorrento Valley Road LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 96. BMR-Sorrento West LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 97. BMR-Spring Mill Drive GP LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware

							
				
	 98. BMR-Spring Mill Drive, L.P.
	  	Limited Partnership	  	1% GP Interest by BMR-Spring Mill Drive GP LLC 99% LP Interest by BioMed Realty, L.P.	  	Delaware
				
	 99. BMR-Torreyana LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 100. BMR-9865 Towne Centre LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 101. BMR-9885 Towne Centre LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 102. BMR-Trade Centre Avenue LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 103. BMR-6611 Tributary Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Maryland
				
	 104. BMR-900 Uniqema Boulevard LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 105. BMR-1000 Uniqema Boulevard LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 106. BMR-325 Vassar Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 107. BMR-3200 Walnut Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 108. BMR-Waples LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 109. BMR-Wateridge LP
	  	Limited Partnership	  	 0% GP Interest by BMR-GP LLC
  

100% LP Interest by BioMed Realty, L.P.
	  	Delaware
				
	 110. BMR-675 West Kendall Street LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 111. BMR-50 West Watkins Mill LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 112. BMR-West Watkins Mill LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware
				
	 113. BMR-Weston LLC
	  	Limited Liability Company	  	100% by BioMed Realty, L.P.	  	Delaware

 SCHEDULE 4.19 

PROJECTS 
  

					
	 Property Name
	  	 Ownership

	1.	 	 1522
217th Place S.E.

Bothell, Washington 98021
	  	Fee Simple
			
	2.	 	 270 Albany Street

Cambridge, Massachusetts 02139-4210
	  	Fee Simple
			
	3.	 	 34790 Ardentech Court

Fremont, California 94555-3657
	  	Fee Simple
			
	4.	 	 34175 Ardenwood Boulevard

Fremont, California 94555
	  	Fee Simple*
			
	5.	 	 Ardsley Park
 (410, 420,
430, 440, 444 and 460 Saw Mill River
 Road, Ardsley, New York 10502)
	  	Fee Simple
			
	6.	 	 8808 Balboa Avenue
 San
Diego, California 92123
	  	Fee Simple
			
	7.	 	 3240, 3260, 3280 Bayshore Blvd
 Brisbane, California 94005
	  	Fee Simple
			
	8.	 	 6411 Beckley Street

Baltimore, Maryland 21224
	  	Fee Simple
			
	9.	 	 9911 Belward Campus Blvd

Rockville, Maryland 20850
	  	Fee Simple
			
	10.	 	 9920 Belward Campus Drive

Rockville, Maryland 20850
	  	Fee Simple
			
	11.	 	 320 Bent Street
 Cambridge,
Massachusetts 02142
	  	Leasehold Interest
			
	12.	 	 301 Binney Street

Cambridge, Massachusetts 02142
	  	Leasehold Interest
			
	13.	 	 301 Binney Street Garage

Cambridge, Massachusetts 02142
	  	Leasehold Interest
			
	14.	 	 Kendall Crossing Apartments

(157 Sixth Street
 Cambridge, Massachusetts
02142)
	  	Leasehold Interest
			
	15.	 	 17190 Bernardo Center Drive

San Diego, California 92128
	  	Fee Simple
			
	16.	 	 3 Blackfan Circle
 Boston,
Massachusetts 02115
	  	Fee Simple

  

					
	 Property Name
	  	 Ownership

	17.	 	 Bridgeview Technology Park

(24500 Clawiter Road
 24600 Industrial
Boulevard
 24546 Industrial Boulevard

Hayward, California 94545)
	  	Fee Simple
			
	18.	 	 Bridgeview Technology Park II

(24590 Clawiter Road
 Hayward, California
94545)
	  	Fee Simple
			
	19.	 	 210 Broadway
 Cambridge,
Massachusetts 02139
	  	Fee Simple
			
	20.	 	 3030 Bunker Hill Street
 San
Diego, California 92109
	  	Fee Simple
			
	21.	 	 58 Charles Street

Cambridge, Massachusetts 02141
	  	Fee Simple
			
	22.	 	 134 Coolidge Avenue

Watertown, Massachusetts 02472
	  	Fee Simple
			
	23.	 	 6300 Dumbarton Circle

Fremont, California 94555
	  	Fee Simple
			
	24.	 	 350 Kendall Street

Cambridge, Massachusetts 02142
	  	Fee Simple*
			
	25.	 	 650 E Kendall Street

Cambridge, Massachusetts 02142
	  	Fee Simple*
			
	26.	 	 475 Eccles Avenue
 South San
Francisco, California 94080
	  	Fee Simple
			
	27.	 	 2600 Eisenhower Road

Norristown, Pennsylvania 19403
	  	Fee Simple
			
	28.	 	 201 Elliott Avenue
 Seattle,
Washington 98119
	  	Fee Simple
			
	29.	 	 21 Erie Street
 Cambridge,
Massachusetts 02139
	  	Fee Simple
			
	30.	 	 40 Erie Street
 Cambridge,
Massachusetts 02139-4254
	  	Fee Simple
			
	31.	 	 47 Erie Street
 Cambridge,
Massachusetts 02139
	  	Fee Simple
			
	32.	 	 4775 and 4785 Executive Drive

San Diego, California 92121
	  	Fee Simple

					
	 Property Name
	  	 Ownership

	 33.
	  	 4570 Executive Drive
 San
Diego, California 92121
	  	Fee Simple
			
	 34.
	  	 500 Fairview Avenue

Seattle, Washington 98109
	  	Leasehold Interest
			
	 35.
	  	 530 Fairview Avenue

Seattle, Washington 98109
	  	Fee Simple
			
	 36.
	  	 2282 Faraday Avenue

Carlsbad, California 92008
	  	Fee Simple
			
	 37.
	  	 530-540 Forbes Boulevard

South San Francisco, California 94080
	  	Fee Simple
			
	 38.
	  	 Fresh Pond Research Park

(25, 27/31, 33/45, 51 and 61 Moulton Street and 665
 Concord Avenue Cambridge, Massachusetts 02138)
	  	Fee Simple
			
	 39.
	  	 700 Gateway Boulevard
 South
San Francisco, California 94080-7023
	  	Fee Simple
			
	 40.
	  	 750, 800, and 850 Gateway Boulevard
 South San Francisco, California 94080-7023
	  	Fee Simple
			
	 41.
	  	 900 Gateway Boulevard
 South
San Francisco, California 94080-7023
	  	Fee Simple
			
	 42.
	  	 1000 Gateway Boulevard

South San Francisco, California 94080-7023
	  	Fee Simple
			
	 43.
	  	 Pacific Research Center

(7333, 7555, 7575, 7677, 7707, 7979, 7999, 7700, 7600, and
 7500 Gateway Boulevard, Newark, California 94560)
	  	Fee Simple
			
	 44.
	  	 2855 Gazelle Court

Carlsbad, California 92010
	  	Fee Simple
			
	 45.
	  	 350 George Patterson Boulevard
 Bristol, Pennsylvania 19007
	  	Fee Simple
			
	 46.
	  	 7 Graphics Drive
 Ewing, New
Jersey 08628
	  	Fee Simple
			
	 47.
	  	 50/60 Hampshire Street

Cambridge, Massachusetts 02139
	  	Fee Simple
			
	 48.
	  	 201 Industrial Road
 San
Carlos, California 94070
	  	Fee Simple
			
	 49.
	  	 3525 John Hopkins Court
 San
Diego, California 92121
	  	Fee Simple

					
	 Property Name
	  	 Ownership

	 50.
	  	 3545-3575 John Hopkins Court

San Diego, California 92121
	  	Fee Simple
			
	 51.
	  	 6500 Kaiser Drive
 Fremont,
California 94555
	  	Fee Simple
			
	 52.
	  	 450 Kendall Street

Cambridge, Massachusetts 02142-1108
	  	Leasehold Interest
			
	 53.
	  	 500 Kendall Street

Cambridge, Massachusetts 02142-1108
	  	Fee Simple
			
	 54.
	  	 145 King of Prussia Road

Radnor, Pennsylvania 19087
	  	Fee Simple
			
	 55.
	  	 Landmark at Eastview
 (735,
745,755, 765, 767, 769, 771, 777 Old Saw Mill River
 Rd., Tarrytown, New York 10591)
 (1 Saw Mill River Road, Hawthorne, New York 10532)
	  	Fee Simple
			
	 56.
	  	 10165 McKellar Court
 San
Diego, California 92121
	  	Fee Simple*
			
	 57.
	  	 9704 and 9708 – 9714 Medical Center Drive
 Rockville, Maryland 20859
	  	Fee Simple
			
	 58.
	  	 3450-3451 Monte Villa Parkway

Bothell, Washington 98021
	  	Fee Simple
			
	 59.
	  	 6114, 6118, 6122, 6124, 6126 and 6154 Nancy Ridge
 Drive, San Diego, California 92121
	  	Fee Simple
			
	 60.
	  	 6828 Nancy Ridge Drive
 San
Diego, California 92121
	  	Fee Simple
			
	 61.
	  	 One Research Way
 Princeton,
New Jersey 08536
	  	Fee Simple
			
	 62.
	  	 180 Oyster Point Boulevard

South San Francisco, California 94080-7023
	  	Fee Simple
			
	 63.
	  	 200 Oyster Point Boulevard

South San Francisco, California94080-7023
	  	Fee Simple
			
	 64.
	  	 5870 and 5880 Pacific Center Boulevard
 San Diego, California 92121
	  	Fee Simple
			
	 65.
	  	 3500 Paramount Parkway

Morrisville, North Carolina 27560
	  	Fee Simple

					
	 Property Name
	  	 Ownership

	 66.
	 	 3908 Patriot Drive
 Durham,
North Carolina 27703
	  	Fee Simple
			
	 67.
	 	 335-339 Phoenixville Pike

Malvern, Pennsylvania 19355
	  	Fee Simple
			
	 68.
	 	 1701 and 1711 Research Boulevard
 Rockville, Maryland 20850
	  	Fee Simple
			
	 69.
	 	 10835 Road to the Cure
 San
Diego, California 92121
	  	Fee Simple
			
	 70.
	 	 10240 Science Center Drive

San Diego, California 92121
	  	Fee Simple
			
	 71.
	 	 10255 Science Center Drive

San Diego, California 92121
	  	Fee Simple
			
	 72.
	 	 14200 Shady Grove Road

Rockville, Maryland 20850
	  	Fee Simple
			
	 73.
	 	 200 Sidney Street

Cambridge, Massachusetts 02139
	  	Fee Simple
			
	 74.
	 	 11404 and 11408 Sorrento Valley Road
 San Diego, California 92121
	  	Fee Simple
			
	 75.
	 	 4215 Sorrento Valley Boulevard
 San Diego, California 92121
	  	Fee Simple
			
	 76.
	 	 11388 Sorrento Valley Road

San Diego, California 92121
	  	Fee Simple
			
	 77.
	 	 11080, 11100, 11120 and 11180 Roselle Street and 11055,
 11095, 11111, 11125, and 11175 Flintkote Avenue,
 San Diego, California 92121
	  	Fee Simple
			
	 78.
	 	 2-30 Spring Mill Drive

Malvern, Pennsylvania 19355
	  	Fee Simple
			
	 79.
	 	 11010 Torreyana Road
 San
Diego, California 92037
	  	Fee Simple
			
	 80.
	 	 9855 and 9865 Towne Centre Drive
 San Diego, California 92121
	  	Fee Simple
			
	 81.
	 	 9875 and 9885 Towne Centre Drive
 San Diego, California 92121
	  	Fee Simple
			
	 82.
	 	 2600 and 2620 Trade Centre Avenue
 Longmont, Colorado 80503
	  	Fee Simple

					
	 Property Name
	  	 Ownership

	 83.
	 	 6611 Tributary Street

Baltimore, Maryland 21224
	  	Fee Simple
			
	 84.
	 	 900 Uniqema Boulevard
 New
Castle, Delaware 19720
	  	Fee Simple
			
	 85.
	 	 1000 Uniqema Boulevard
 New
Castle, Delaware 19720
	  	Fee Simple
			
	 86.
	 	 325 Vassar Street

Cambridge, Massachusetts 02139-4818
	  	Fee Simple
			
	 87.
	 	 9535 Waples Street
 San
Diego, California 92121
	  	Fee Simple
			
	 88.
	 	 1825, 1865, 1885 33rd Street/ 3200 Walnut Street
 Boulder, Colorado 80301
	  	Fee Simple
			
	 89
	 	 10420, 10480, 10520 Wateridge Circle
 San Diego, California 92121
	  	Fee Simple
			
	 90.
	 	 675 West Kendall Street

Cambridge, Massachusetts 02142-1110
	  	Fee Simple
			
	 91.
	 	 50 West Watkins Mill Road

Gaithersburg, Maryland 20878
	  	Fee Simple
			
	 92.
	 	 55 and 65 West Watkins Mill Road
 Gaithersburg, Maryland 20878
	  	Fee Simple
			
	 93.
	 	 3000 Weston Parkway
 Cary,
North Carolina 27513
	  	Fee Simple

  

	*	Such properties are owned by Investment Affiliates of Borrower.Employment Agreement between the Company and Bryan A. Sinclair

 Exhibit 10.9 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (the
“Agreement”) is made and entered into effective as of the 5th day of March, 2011 by and between NYTEX Energy Holdings, Inc., a Delaware corporation (the “Company”), and Bryan Sinclair (the “Executive”). 

WHEREAS, the Company desires to employ the Executive, and the Executive desires to be employed with the Company. 

WHEREAS, the Executive will serve as the Company’s Vice President of Finance. 

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the parties agree as follows: 

ARTICLE 1 

TERM OF EMPLOYMENT 
 1.1 Term of Employment. The Company hereby agrees to employ the Executive and the Executive hereby accepts such employment upon the terms and conditions set forth in this Agreement.
The Executive’s employment with the Company pursuant to this Agreement shall be “at will”, and either the Company or the Executive may terminate the employment relationship at any time in accordance with the provisions of Paragraph
4.1. The period during which the Executive is in fact employed by the Company pursuant to this Agreement shall constitute the “Employment Period” hereunder. 
 ARTICLE 2 
 EMPLOYMENT DUTIES 

2.1 Title/Responsibilities. The Executive shall serve as the Vice President of Finance of the Company. The Executive shall perform
such duties as are usual and customary for such position or any other duties which may be reasonably assigned by the Company’s Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”) or Board from time to time, and
shall report directly to the Company’s CFO. The Executive shall devote his full business time and attention to the business and affairs of the Company during the Employment Period. The Executive shall not engage in any other business, job or
consulting activity during the Employment Period without the prior written permission of the Board. 
 2.2 Location. The
Executive’s principal place of employment shall be the Company’s principal offices in Dallas, Texas, but the Executive may be required from time to time to travel to other geographic locations in connection with the performance of his
duties hereunder. 
 ARTICLE 3 
 COMPENSATION AND BENEFITS 
 3.1 Salary. The Executive shall be paid
a base salary at the annualized rate of One Hundred Sixty Thousand Dollars ($160,000). 
 Such rate shall be subject to annual
review by the Board and may be increased in the Board’s discretion. 
 Base salary may not be decreased below the initial
rate or below the increased rate except that it may be decreased proportionately in connection with an across the board reduction in base salary applying to all executive officers of the Company. Base salary shall be paid at periodic intervals in
accordance with the Company’s payroll practices for salaried employees. 
 3.2 Sign-on Bonus.
The Executive shall be entitled to a one-time sign-on cash bonus equal to 15% of the annualized base salary reflected in Paragraph 3.1. Such bonus shall be paid by the 15th day of the first calendar month following the effective date of this agreement. 

3.3 Bonus. For each fiscal year of the Company during the Employment Period, the Executive shall be eligible to receive a cash
bonus in a dollar amount determined by the Board at its sole discretion. The target bonus for each year shall be 35% of the Executive’s base salary earned during such fiscal year. The actual bonus payable for each fiscal year shall depend upon
the Executive’s performance and the extent to which the Executive has achieved the performance goals established for the Company and the Executive for that year. Any bonus awarded to the Executive shall be paid on the 15th day of the third
calendar month following the close of the fiscal year for which such bonus is earned. 

 3.4 Stock Awards. Executive will be eligible to participate in a stock incentive
award plan for key employees of the Company and his shares will be granted as follows: 
 (i) Upon the execution of the Agreement
by both parties, 50,000 shares of NYTEX Energy Holdings, Inc. Common Stock (“NYTEX Stock”) at an issuance exercise price equal to the fair market value of NYTEX Stock at such grant date 

((ii) 2012; 75,000 shares of NYTEX Stock at an issuance price equal to the fair market value of NYTEX Stock at the specific grant date of
the shares. 
 (iii) 2013; 75,000 shares of NYTEX Stock at an issuance price equal to the fair market value of NYTEX Stock at the
specific grant date of the shares. 
 The stock incentive award, if earned, shall be granted to Executive within 90 days of the
Company’s fiscal year end and will vest over a (3) three year period in equal amounts per year. 
 3.5 Fringe
Benefits. The Executive shall, throughout the Employment Period, be eligible to participate in all employee benefit plans and programs, such as group disability insurance and group medical plans, which may be made available to the Company’s
full-time employees from time to time and for which Executive qualifies. 
 3.6 Vacation and Holidays. Executive will be
entitled to receive paid vacation of not less than fifteen (15) days and paid holidays in accordance with then-current Company policy. 
 3.7 Expense Reimbursement. The Executive shall be entitled, in accordance with the Company’s reimbursement policies in effect from time to time, to receive reimbursement from the Company for
all reasonable business expenses incurred by the Executive in the performance of his duties hereunder, provided the Executive furnishes the Company with vouchers, receipts and other details of such expenses in the form required by the Company
sufficient to substantiate a deduction for such business expenses under all applicable rules and regulations of federal and state taxing authorities (the “Supporting Documentation”). The Executive must submit the Supporting Documentation
for each such expense within ninety (90) days after the Executive’s incurrence of such expense. If such expense qualifies hereunder for reimbursement, then the Company shall reimburse the Executive for that expense within thirty
(30) days thereafter. 
 3.8 Withholding. The Company shall deduct and withhold from the compensation payable to the
Executive hereunder any and all applicable federal, state and local income and employment withholding taxes and any other amounts required to be deducted or withheld by the Company under applicable statutes, regulations, ordinances or orders
governing or requiring the withholding or deduction of amounts otherwise payable as compensation or wages to employees. 

ARTICLE 4 

TERMINATION 
 4.1 Termination of Employment. The Executive’s employment pursuant to this Agreement is “at will” and may be terminated in accordance with the following provisions: 

A. The Executive’s employment under this Agreement shall terminate immediately upon the Executive’s death during the Employment
Period. 
 B. In the event of the Executive’s Incapacity for a period of one hundred fifty (150) days during the
Employment Period, the Company may provide written notice of termination of the Executive’s employment under this Agreement. The Executive’s employment shall terminate on the thirtieth (30)-day following receipt of such notice by the
Executive provided that, within such thirty (30)-day period, the Executive shall not have returned to full-time performance of the Executive’s essential job functions. Notwithstanding the foregoing, the Executive’s employment under this
Agreement shall terminate without further obligation or notice by the Company, upon the Executive’s Incapacity for an aggregate period of two hundred ten (210) days, in whole or in part, in any twelve (12)-month period during the
Employment Period. 
 C. The Company may at any time, upon written notice, terminate the Executive’s employment under this
Agreement for any reason. 
 D. The Executive may at any time, upon thirty (30) days written notice, terminate his
employment under this Agreement for any reason. 

  
 2 

 E. The Company may at any time, upon written notice, discharge the Executive from employment
with the Company hereunder by reason of Misconduct. Such termination shall be effective immediately upon such notice. 
 4.2
Payments Due Upon Any Termination. Upon any termination of the Executive’s employment during the Employment Period, the Company shall provide to the Executive (or his estate) any unpaid base salary earned under Paragraph 3 for services
rendered through the date of termination. All vesting of the Executive’s outstanding restricted stock, options, or other equity awards granted shall cease at the time of his termination of employment, and the Executive (or his estate) shall not
have more than the limited period of time specified in the applicable stock compensation agreement in which to exercise any outstanding option following such termination of employment for any Common Shares for which those options are vested and
exercisable at the time of such termination. In addition, the Executive shall be eligible for the payments and other benefits provided under Paragraph 4.3 or Paragraph 4.4 below of this Agreement, to the extent he qualifies for those payments and
benefits in accordance with the applicable provisions of this Agreement. 
 4.3 Severance Benefits Upon Involuntary
Termination Other Than Change in Control Severance Benefits. Should the Executive’s employment pursuant to this Agreement be terminated by the Company other than by reason of Misconduct at any time other than within the Change in Control
Severance Period, then the Executive shall become eligible to receive the severance payments and benefits described below provided that there is compliance with the following requirements (the “Severance Benefits Conditions”): 

(i) The Executive shall, within twenty-one (21) days (or within forty-five (45) days if such longer period is required under
applicable law) following such termination, execute and deliver to the Company a general release in substantially the form attached hereto as Exhibit B which becomes effective in accordance with applicable law following the expiration of any
applicable revocation period. This requirement shall hereinafter be referred to as the “Release Condition.” 
 (ii) The
Executive shall have complied with, and shall continue to comply with the restrictive covenants set forth in Paragraph 4.5. 

In the event that the Executive elects to engage or otherwise engages in any of the activities precluded by the restrictive covenants set
forth in Paragraph 4.5, the Executive shall not be entitled, after the date of such violation or activity (as the case may be), to receive any payments or benefits under Paragraph 4.3 or Paragraph 4.4. 

The severance payments and benefits to which the Executive may become entitled under this Paragraph 4.3 shall consist of the following:

 (a) Salary Continuation Payments. The Executive shall be eligible to receive his base salary for a total period
of nine (9) months at the annualized rate then in effect for him under Paragraph 3 at the time of his termination. The first such payment shall be made on the thirtieth (30th) day following the Executive’s Separation from Service due
to such termination provided the requisite Release Condition is satisfied and subsequent salary continuation payments shall be made at periodic intervals in accordance with the Company’s payroll practices for salaried employees. 

(b) Health Care Coverage. Provided the Executive and his spouse and eligible dependents elect to continue medical care
coverage under the Company’s group health care plans pursuant to the applicable COBRA provisions, the Company shall provide, at its cost, continued medical care coverage for the Executive, his spouse and his eligible dependents until the
earliest to occur of (i) the expiration of the nine (9)-month period measured from the first day of the calendar month following the calendar month in which his termination occurs or (ii) the first date on which the Executive and his
spouse and eligible dependents are covered under another employer’s health benefit program without exclusion for any pre-existing medical condition. During the period such medical care coverage remains in effect hereunder, the following
provisions shall govern the arrangement: (a) the amount of such benefits in any one calendar year of such coverage shall not affect the amount of benefits in any other calendar year for which such benefits are to be provided hereunder and
(b) the Executive’s right to the benefits cannot be liquidated or exchanged for any other benefit. 
 The foregoing
benefits shall be in lieu of any other severance benefits for which the Executive might otherwise be eligible by reason of his termination of employment under the circumstances specified in this Paragraph 4.3. 

4.4 Change in Control Severance Benefits. Should the Executive’s employment pursuant to this Agreement terminate by reason of
an Involuntary Termination within the Change in Control Severance Period, then the Executive shall become eligible to receive the following payments and benefits provided there is compliance with the same Severance Benefit Conditions set forth in
Paragraph 4.3: 

  
 3 

 (a) Salary Continuation Payments. The Executive shall be eligible to receive
his base salary for up to a total period of twelve (12) months at the annualized rate then in effect for him under Paragraph 3 at the time of his Involuntary Termination. The first such payment shall be made on the thirtieth (30th) day
following the Executive’s Separation from Service due to such Involuntary Termination provided the requisite Release Condition is satisfied and subsequent salary continuation payments shall be made at periodic intervals in accordance with the
Company’s payroll practices for salaried employees. 
 (b) Pro-Rata Bonus. The Executive shall be entitled to
receive a pro-rata amount of the annual bonus for the fiscal year in which the termination occurs provided and only to the extent that any applicable performance goals upon which such bonus is conditioned are attained at the time of Executive’s
separation, and provided in its sole discretion, the Company elects to make such bonus to its other Executives. In the event of such attainment, the pro-rata bonus to which the Executive shall become entitled shall be determined by multiplying
(i) the actual bonus the Executive would have received based on the attained performance goals had the Executive continued in the Company’s employ until the payment date of that bonus by (ii) a fraction, the numerator of which is the
number of full completed months in the bonus plan year through the effective date of termination, and the denominator of which is twelve (12). This payment shall be made in the fiscal year following the year of the Executive’s termination but
no later than the fifteenth day of the third calendar month of such subsequent year. This payment shall be in lieu of any other payment to be made to the Executive under such annual bonus plan for such fiscal year. 

(c) Health Care Coverage. Provided the Executive and his spouse and eligible dependents elect to continue medical care
coverage under the Company’s group health care plans pursuant to the applicable COBRA provisions, the Company shall provide, at its cost, continued medical care coverage for the Executive, his spouse and his eligible dependents until the
earliest to occur of (i) the expiration of the twelve (12)-month period measured from the first day of the calendar month following the calendar month in which his Involuntary Termination occurs or (ii) the first date on which the
Executive and his spouse and eligible dependents are covered under another employer’s health benefit program without exclusion for any pre-existing medical condition. During the period such medical care coverage remains in effect hereunder, the
following provisions shall govern the arrangement: (a) the amount of such benefits in any one calendar year of such coverage shall not affect the amount of benefits in any other calendar year for which such benefits are to be provided hereunder
and (b) the Executive’s right to the benefits cannot be liquidated or exchanged for any other benefit. 
 The
severance payments and benefits provided under this Paragraph 4.4 shall be in lieu of any other severance benefits for which the Executive might otherwise be eligible by reason of the termination of his employment during the Change in Control
Severance Period. 
 In the event that the Executive elects to engage or otherwise engages in any of the activities precluded by
the restrictive covenants set forth in Paragraph 4.5, the Executive shall not be entitled, after the date of such violation or activity (as the case may be), to receive any payments or benefits under Paragraph 4.4. 

In no event shall the Executive be entitled to benefits and payments under both Paragraphs 4.3 and 4.4 of this Agreement. 

4.5 Restrictive Covenants. During the Employment Period and for the entire period during which the Executive is to receive salary
continuation payments under Paragraph 4.3 or Paragraph 4.4 below, whether or not those salary continuation payments are delayed pursuant to Paragraph 5.1, the Executive shall not: 

(i) reveal, disclose, use or otherwise utilize any confidential, proprietary information of the Company, including, but not limited to its
customer and vendor information, pricing, discounts, and other sales terms for Customers, financial plans and projections, budget, methodologies, tools, techniques and other methods of doing business unique to Company and which provide Company a
competitive advantage, which is not in the public domain, hereafter “Confidential Information.” This Confidential Information shall be provided to Executive by the Company to enable him to successfully perform his job responsibilities, and
Executive covenants not to use, disclose or reveal this Confidential Information, except as authorized by the Company for its benefit. 
 (ii) anywhere in the United States render any services or provide any advice, assistance or support to any Competing Business, whether as an employee, agent, representative, consultant, partner, officer,
director or stockholder or in any other capacity; provided, however, that the Company acknowledges and agrees that the Executive may make a passive investment representing an interest of less than five percent (5%) of an outstanding class of
publicly-traded securities of any corporation or other enterprise which may constitute a Competing Business hereunder; 

  
 4 

 (iii) contact, solicit or call upon any customer of the Company with whom Executive worked
or about which Executive received Confidential Information, on behalf of any person or entity other than the Company for the purpose of selling any products or providing or performing any services of the type normally sold, provided or performed by
the Company; 
 (iv) induce or attempt to induce any person or entity to curtail or cancel any business or contracts which such
person or entity has with the Company; 
 (v) directly or indirectly encourage or solicit any employee, consultant or independent
contractor to leave the employment or service of the Company (or any affiliated company) for any reason or interfere in any other manner with any employment or service relationships at the time existing between the Company (or any affiliated
company) and its employees, consultants and independent contractors; or 
 (vi) directly or indirectly solicit any vendor,
supplier, licensor, licensee or other business affiliate of the Company (or any affiliated company) or directly or indirectly induce any such person to terminate its existing business relationship with the Company (or affiliated company) or
interfere in any other manner with any existing business relationship between the Company (or any affiliated company) and any such vendor, supplier, licensor, licensee or other business affiliate. 

4.6 Benefit Limit. The benefit limitations of this Paragraph 4.5 shall be applicable in the event the Executive receives any
benefits that are deemed to constitute parachute payments under Code Section 280G. 
 In the event that any payments to
which the Executive becomes entitled in accordance with the provisions of this Agreement (or any other benefits to which the Executive may become entitled in connection with any change in control or ownership of the Company or the subsequent
termination of his employment with the Company) would otherwise constitute a parachute payment under Code Section 280G, then such payments and benefits shall be subject to reduction to the extent necessary to assure that the Executive receives
only the greater of (i) the amount of those payments or benefits which would not constitute such a parachute payment or (ii) the amount which yields the Executive the greatest after-tax amount of benefits after taking into account any
excise tax imposed on the payments provided to the Executive under this Agreement (or on any other benefits to which the Executive may become entitled in connection with any change in control or ownership of the Company or the subsequent termination
of his employment with the Company) under Code Section 4999. 
 Should a reduction in benefits be required to satisfy the
benefit limit of this Paragraph 4.6, then the Executive’s salary continuation payments under Paragraph 4.3 or 4.4, as applicable, shall accordingly be reduced (with such reduction to be effected pro-rata to each payment) to the extent necessary
to comply with such benefit limit. Should such benefit limit still be exceeded following such reduction, then the number of shares as to which any equity award would otherwise vest on an accelerated basis in accordance with the terms of the award
shall be reduced (based on the value of the parachute payment attributable to such equity award under Code Section 280G) to the extent necessary to eliminate such excess. 
 ARTICLE 5 
 MISCELLANEOUS PROVISIONS 

5.1 Section 409A. 
 A. It is the intention of the parties that the provisions of this Agreement either be exempt from, or comply with, the requirements of Section 409A of the Code and the Treasury Regulations
thereunder. Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Agreement would otherwise contravene the applicable requirements or limitations of Code Section 409A, then those provisions shall be
interpreted and applied in a manner that does not result in a violation of the applicable requirements or limitations of Code Section 409A and the Treasury Regulations thereunder. In no event may Executive, directly or indirectly, designate the
calendar year of a payment. 
 B. Notwithstanding any provision to the contrary in this Agreement, no payments or benefits to
which the Executive becomes entitled under Paragraph 4.3 or 4.4 of this Agreement shall be made or paid to the Executive prior to the earlier of (i) the first business day of the seventh month following the date of the
Executive’s Separation 

  
 5 

 
from Service or (ii) the date of the Executive’s death, if (a) the Executive is deemed at the time of such Separation from Service a “specified employee” within the
meaning of that term under Section 409A of the Code, (b) the stock of the Company or any successor entity is publicly traded on an established market and (c) such delayed commencement is otherwise required in order to avoid a
prohibited distribution under Code Section 409A(a)(2). Upon the expiration of the applicable deferral period, all payments deferred pursuant to this Paragraph 5.1 shall be paid in a lump sum to the Executive, and any remaining payments,
benefits or reimbursements due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. 
 5.2 No Entitlement to Benefits. In no event shall the Executive be entitled to any benefits under Paragraph 4.3 or 4.4 of this Agreement if his employment ceases by reason of Misconduct, death or
Incapacity or if he voluntarily resigns (other than, in connection with a termination during the Change in Control Severance Period, for a reason which qualifies as Good Reason). 

5.3 Successors and Assigns. The provisions of this Agreement shall inure to the benefit of, and shall be binding upon,
(i) the Company and its successors and assigns, including any successor entity by merger, consolidation or transfer of all or substantially all of the Company’s assets (whether or not such transaction constitutes a Change in Control), and
(ii) the Executive, the personal representative of his estate and his heirs and legatees. 
 5.4 Notices.

 A. Any and all notices, demands or other communications required or desired to be given hereunder by any party shall be in
writing and shall be validly given or made to another party if delivered either personally or if deposited in the United States mail, certified or registered, postage prepaid, return receipt requested. If such notice, demand or other communication
shall be delivered personally, then such notice shall be conclusively deemed given at the time of such personal delivery. 
 B.
If such notice, demand or other communication is given by mail, such notice shall be conclusively deemed given forty-eight (48) hours after deposit in the United States mail addressed to the party to whom such notice, demand or other
communication is to be given as hereinafter set forth: 
 To the Company: 

NYTEX Energy Holdings, Inc. 
 12222 Merit Drive, Suite 1850 
 Dallas, Texas 75251 

Attention: Chief Executive Officer 
 To the Executive: 
 Bryan Sinclair 

15751 Custer Trail 
 Frisco, Texas 75035 
 C. Any party hereto may change its address for the purpose
of receiving notices, demands and other communications as herein provided by a written notice given in the manner aforesaid to the other party hereto. 
 5.5 General Creditor Status. The benefits to which the Executive may become entitled under Article 4 of this Agreement shall be paid, when due, from the Company’s general assets, and no trust
fund, escrow arrangement or other segregated account shall be established as a funding vehicle for such payments. 

Accordingly, the Executive’s right (or the right of the executors or administrators of the Executive’s estate) to receive such
benefits shall at all times be that of a general creditor of the Company and shall have no priority over the claims of other general creditors. 
 5.6 Governing Documents. This Agreement shall constitute the entire agreement and understanding of the Company and the Executive with respect to the terms and conditions of the Executive’s
employment with the Company and the payment of severance benefits and shall supersede all prior and contemporaneous written or verbal agreements and understandings between the Executive and the Company relating to such subject matter. 

5.7 Governing Law. The provisions of this agreement shall be construed and interpreted under the laws of the State of Texas
applicable to agreements executed and wholly performed within the State of Texas. If any provision of this Agreement as applied to any party or to any circumstance should be adjudged by a court of

  
 6 

 
competent jurisdiction or determined by an arbitrator to be void or unenforceable for any reason, the invalidity of that provision shall in no way affect (to the maximum extent permissible by
law) the application of such provision under circumstances different from those adjudicated by the court or determined by the arbitrator, the application of any other provision of this Agreement, or the enforceability or invalidity of this Agreement
as a whole. Should any provision of this Agreement become or be deemed invalid, illegal or unenforceable by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to
applicable law so as to be valid and enforceable and consistent with the intent of the parties hereto. If such provision cannot be so amended without altering the intention of the parties, then such provision, including any consideration
specifically tied to such provision, shall be stricken and the remainder of this Agreement shall continue in full force and effect. It is the express intent of the parties that should any of the severance benefit conditions of paragraph 4.3 or 4.4
be void or unenforceable as written herein then Executive shall not be entitled to any additional severance payments or benefits under paragraph 4.3 or under paragraph 4.4 (as the case may be). 

5.8 Exclusive Venue. The exclusive venue for any dispute arising out of this Agreement shall be in the courts of Dallas County,
Texas. 
 5.9 Legal Representation. The Executive acknowledges that he has had the right to consult with counsel and is
fully aware of his rights and obligations under this Agreement. 
 5.10 Counterparts. This Agreement may be executed in
more than one counterpart, each of which shall be deemed an original, but all of which together shall constitute but one and the same instrument. 
 ARTICLE 6 
 DEFINITIONS 

For purposes of this Agreement, the following definitions shall be in effect: 
 Board means the Company’s Board of Directors. 
 Change in Control means a change
in control of the Company effected through any of the following transactions: 
 (i) a merger, consolidation or other
reorganization approved by the Company’s shareholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor company are immediately thereafter
beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company’s outstanding voting securities immediately prior to such transaction, or 

(ii) a shareholder-approved sale, transfer or other disposition of all or substantially all of the Company’s assets in liquidation or
dissolution of the Company, or 
 (iii) the acquisition, directly or indirectly by any person or related group of persons (other
than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty
percent (50%) of the total combined voting power of the Company’s outstanding securities pursuant to a tender or exchange offer made directly to the Company’s shareholders, or 

(iv) a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the
Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or
nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination. 

Change in Control Severance Period means the period commencing with the Company’s execution of the definitive agreement for a Change in
Control transaction and continuing until the end of the twenty-four (24)-month period measured from the closing date of that Change in Control. 

Code means the Internal Revenue Code of 1986, as amended. 
 Common Stock means the Company’s common stock. 
 Competing Business means any
business which is or, to the best of the Executive’s knowledge, is expected to become, competitive with (a) the business of the Company (or any direct or indirect subsidiaries of the Company or any of their affiliates) or (b) a
product or service that was contemplated by the Company (or any direct or indirect subsidiaries of the Company or any of their affiliates) during the six (6)-month period prior to the termination of Executive’s employment. 

  
 7 

 Employment Period means the Employment Period as defined in Paragraph 1 of this Agreement.

 Good Reason means the Executive’s voluntary resignation within thirty (30) days following one or more of the following events
that occur without the Executive’s written consent: (A) a change in the Executive’s position with the Company (or an affiliate of the Company then employing the Executive) which materially reduces the Executive’s duties and
responsibilities under Paragraph 2.1, (B) a material reduction in the Executive’s level of compensation (including base salary and target bonuses under any corporate-performance based incentive programs), with a ten percent
(10%) reduction deemed to be material, (C) a relocation of his principal place of employment by more than fifty (50) miles from the location of his principal office in Dallas, Texas; provided, however, that none of the events
specified above shall constitute Good Reason unless the Executive first provides written notice to the Company describing the applicable event within thirty (30) days following the occurrence of that event and the Company fails to cure such
event within thirty (30) days after receipt of such written notice. 
 Incapacity means the inability of the Executive, by reason of
any injury or illness, to properly perform the essential job functions, with our without reasonable accommodation, duties and responsibilities under this Agreement. 
 Involuntary Termination means (i) the Executive’s involuntary dismissal or discharge by the Company for reasons other than Misconduct or (ii) the Executive’s voluntary
resignation for Good Reason. An Involuntary Termination shall not include the termination of the Executive’s employment by reason of death or Incapacity. 
 Misconduct means (i) the commission of any act of fraud or embezzlement by the Executive, (ii) any unauthorized use or disclosure by the Executive of confidential information or trade
secrets of the Company (or any affiliate of the Company), or (iii) any other intentional misconduct by the Executive adversely affecting the business or affairs of the Company (or any affiliate of the Company) in a material manner. The
foregoing definition shall not be deemed to be inclusive of all the acts or omissions which constitute misconduct or for which the Company (or any affiliate of the Company) may consider as grounds for the dismissal or discharge of the Executive or
any other individual. 
 1934 Act means the U.S. Securities Exchange Act of 1934, as amended. 

Separation from Service means the Executive’s cessation of Employee status and shall be deemed to occur at such time as the level of the bona
fide services the Executive is to perform in employee status (or as a consultant or other independent contractor) permanently decreases to a level that is not more than twenty percent (20%) of the average level of services the Executive
rendered in employee status during the immediately preceding thirty-six (36) months (or such shorter period for which the Executive may have rendered such service). Any such determination as to Separation from Service, however, shall be made in
accordance with the applicable standards of the Treasury Regulations issued under Code Section 409A. 

  
 8 

 IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of the dates indicated
below. 
 NYTEX ENERGY HOLDINGS, INC. 
 By: /s/ Kenneth K. Conte                     

Title: EVP / CFO             

Dated: March 5, 2011                 

THE EXECUTIVE 
 /s/ Bryan A. Sinclair                     

By: Bryan Sinclair 
 Dated: March 5, 2011             

  
 9 

 GENERAL RELEASE 
 In consideration of certain severance payments by NYTEX Energy Holdings, Inc., a Delaware corporation (hereafter for “Company”), as set forth in the Employment Agreement dated as
of [            ] (the “Employment Agreement”) and other consideration set forth therein, I, Bryan Sinclair, hereby execute the following General Release
“Release”) and hereby agree as follows related to my prior employment by the Company or its affiliates which is terminated today,             ,
20             (the “Termination Date”, and unless modified by paragraph 8 below, the Termination Date shall be the “Effective Date” of this
Release): 
 1. Payment of Wages. I acknowledge that I have been paid all salary, wages, bonuses, accrued vacation and any
and all other compensation and/or benefits owed to me by the Company, other than the severance owed to me pursuant to the Employment Agreement which will be paid to me in accordance with the terms of the Employment Agreement. 

2. Release of Claims. In exchange for the consideration provided above, I on behalf of myself and my heirs, family members,
executors and assigns, hereby expressly waive, release, acquit and forever discharge the Company and its predecessors, successors, assigns, divisions, subsidiaries, affiliates, parents, officers, directors, executives, managers, supervisors,
employees, partners, agents, attorneys and representatives (hereinafter the “Released Parties”), from any and all claims, demands, and causes of action which I have or claim to have, whether known or unknown, of whatever
nature, which exist or may exist as of the date of this Release. As used in this paragraph, “claims,” “demands,” and “causes of action” include, but are not limited to, contract claims, equitable claims, fraud claims,
tort claims, discrimination claims, harassment claims, retaliation claims, personal injury claims, emotional distress claims, public policy claims, claims for stock options and/or for vesting or accelerated vesting of options or stock, claims for
severance pay, vacation pay, debts, accounts, attorneys’ fees, 
 compensatory damages, punitive damages, and/or liquidated damages, and
any and all claims arising under the Americans with Disabilities Act of 1990, the Family and Medical Leave Act, or any other federal, state or local statute governing employment, including but not limited to Title VII of the Civil Rights Act of
1964, the Civil Rights Act of 1991, the Age Discrimination in Employment Act, 29 U.S.C. §§ 621, et seq., as amended by the Older Workers Benefit Protection Act, the Consolidated Omnibus Budget Reconciliation Act of 1985, the
Employee Retirement Income Security Act of 1974, the Texas Commission on Human Rights Act, Texas Labor Code §§ 21.001, et seq., Texas Labor Code §§ 451.001, et seq., the Texas Payday Act, all employment laws of any
state in which I have worked during my employment with the Company, or any amendments to the above acts. 
 3. Release of
Claims for Age Discrimination. Without in any way limiting the generality or scope of the above paragraph, I hereby understand and agree to release any and all claims, rights or benefits I may have arising out of or under the Age Discrimination
in Employment Act of 1967 (“ADEA”), 29 U.S.C. § 621, et seq., as amended by the Older Workers Benefit Protection Act, or any equivalent or comparable provision of federal, state or local law, including, without
limitation, the Texas Commission on Human Rights Act and any age discrimination laws of any state in which I have worked during my employment with the Company. 
 4. Exceptions. This Release excludes any claim which cannot be released by private agreement, such as workers’ compensation claims, unemployment claims, claims after the Effective Date of this
Release, and the right to file administrative charges with certain government agencies. 
 5. Non-Admission of Liability.
I understand that nothing in this Release shall constitute or be treated as an admission of any wrongdoing or liability on the part of the Company, and/or the Released Parties. 

6. Consultation With an Attorney. I acknowledge that I have been advised to consult with an attorney prior to entering into this
Release. 
 7. Acceptance of Release. If I am forty (40) years of age or older as of the date I sign this Release,
(a) I acknowledge that I have 21 days from the termination of my employment to consider this Release and that I may revoke this Release at any time during the first seven days following my execution of this Release by delivering written notice
of revocation to NYTEX Energy Holdings, Inc., 12222 Merit Drive, Suite 1850, Dallas, TX 75251; (b) I acknowledge that the earliest date I may sign this Release is on my last day of employment; (c) I acknowledge

  

			
	 1
	 	GENERAL RELEASE

 
that this Release will become effective, fully enforceable and irrevocable seven days after I sign the Release, provided that I do not exercise my revocation right as indicated above (the date
seven days after signing, the “Effective Date”). I represent that if I execute this Release before the 21-day consideration period has passed, I do so voluntarily, and I knowingly and voluntarily waive my option to use the
entire 21 days to consider this Release. 
 8. No Filing of Claims. I represent and warrant that I do not presently have
on file, and further represent and warrant to the maximum extent allowed by law that I will not hereafter file any lawsuits or claims against the Company and/or the Released Parties in or with any state or federal court, or before any other tribunal
or panel or arbitrators, public or private, based upon any actions or omissions by the Company and/or the Released Parties occurring prior to the date of this Release, with the exception of claims brought to challenge the validity of this Release
under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act. Nothing in this Release shall be construed to prohibit me from filing a charge with or participating in any investigation or proceeding conducted
by the Equal Employment Opportunity Commission, National Labor Relations Board, or a comparable state or local agency; however, I agree to waive any right to recover monetary damages through any such charge. 

9. Confidentiality. I agree to keep this Release confidential and not to reveal its contents to anyone except my lawyer, my spouse
and/or my financial consultant (and then only after obtaining the agreement of such person to maintain such confidentiality). 

10. Non-Disparagement. I agree that I will not disparage or in any way criticize the Company and/or its officers, managers,
supervisors, employees, investors, products, services; or technology at any time in the future. Nothing contained in this Section is intended to prevent me from testifying truthfully in any legal proceeding. 

11. No Cooperation. I agree that I will not counsel or assist any attorneys or their clients in the presentation or prosecution of
any disputes, differences, grievances, claims, charges, or complaints by any non-governmental third party against the Company and/or any officer, director, employee, agent, representative, stockholder or attorney of the Company, unless under a
subpoena or other court order to do so or as otherwise authorized by law. 
 12. Attorneys’ Fees. I understand and
agree that in any dispute between me and the Company regarding the terms of this Release and/or any alleged breach thereof, that the prevailing party will be entitled to recover its costs and reasonable attorneys’ fees arising out of such
dispute, except that the Company shall not, by virtue of this Release, be entitled to recover its costs or attorney’s fees resulting from challenges to the validity of this Release by me under the Age Discrimination in Employment Act, as
amended by the Older Workers Benefit Protection Act. Nothing in this Release is intended to preclude the Company from recovering attorney’s fees or costs specifically authorized under federal law. 

13. Severability. I acknowledge and agree that each agreement and covenant set forth herein constitutes a separate agreement
independently supported by good and adequate consideration and that each such agreement shall be severable from the other provisions of this Release and shall survive this Release. 

14. Changes to Release. No changes to this Release can be effective except by another written agreement signed by me and the
Company’s CEO. 
 15. Complete Agreement. This Release cancels, supersedes and replaces any and all prior agreements
(written, oral or implied-in-fact or in-law) between the Company and me regarding all of the subjects covered by this Release. This Release is the full, complete and exclusive agreement between the Company and me regarding all of the subjects
covered by this Release, and neither the Company nor I is relying on any representation or promise that is not expressly stated in this Release. 
 16. Voluntary Agreement. I UNDERSTAND AND AGREE THAT I MAY BE WAIVING SIGNIFICANT LEGAL RIGHTS BY SIGNING THIS RELEASE, AND REPRESENT THAT I HAVE ENTERED INTO THIS AGREEMENT VOLUNTARILY, AFTER
HAVING THE OPPORTUNITY TO CONSULT WITH AN ATTORNEY OF MY OWN CHOOSING, WITH A FULL UNDERSTANDING OF AND IN AGREEMENT WITH ALL OF ITS TERMS. 

  

			
	 2
	 	GENERAL RELEASE

 Do not sign this Release before the Termination Date. If you sign this letter before the
Termination Date, you will not be entitled to receive the benefits described in the Employment Agreement. 
 IN WITNESS
WHEREOF, I have executed this Release on the date provided below. 
 Signature:    
___________________________ 
      Bryan Sinclair 

Dated:     ___________________________         

Witness:     ____________________________ 
 Print Name:    __________________________ 

  

			
	 3
	 	GENERAL RELEASE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]